Shivang Chaudhary, Kaushik Gokul, Simran Bhimani, Anand Maligireddy, Nirav Arora, Lolita Golemi, Adam Kilian, Ravi Nayak, Deana Mikhalkova, Chaitanya Rojulpote, Chien-Jung Lin
{"title":"了解肺结节病与心脏结节病患者的患病率、住院死亡率和再入院率:来自全国登记的见解","authors":"Shivang Chaudhary, Kaushik Gokul, Simran Bhimani, Anand Maligireddy, Nirav Arora, Lolita Golemi, Adam Kilian, Ravi Nayak, Deana Mikhalkova, Chaitanya Rojulpote, Chien-Jung Lin","doi":"10.62347/WJWP6904","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Sarcoidosis is a multisystem granulomatous disorder, with pulmonary sarcoidosis (PS) affecting approximately 90% of patients and cardiac sarcoidosis (CS) being less common but associated with severe clinical implications. While PS is primarily characterized by respiratory symptoms, CS can lead to serious complications like heart failure and arrhythmias, contributing to sarcoidosis-related mortality. This study aims to compare the prevalence, in-hospital mortality, 30-day readmission rates, and healthcare costs between PS and CS patients using data from the Nationwide Readmissions Database (NRD).</p><p><strong>Methods: </strong>Data were extracted from the NRD for adult patients diagnosed with PS or CS from January 2016 to December 2020. Baseline demographics, comorbidities, in-hospital outcomes, and 30-day readmission rates were analyzed. Statistical comparisons were made using appropriate tests for categorical and continuous variables.</p><p><strong>Results: </strong>Among 101,365 patients, 96,905 had PS and 4,460 had CS. CS patients experienced significantly higher rates of cardiovascular complications, such as heart failure (77.1% vs. 31.1%) and arrhythmias (75.8% vs. 27.7%), and incurred higher hospital charges ($59,520 vs. $40,249; P < 0.001). In-hospital mortality was similar between groups (CS: 2.4% vs. PS: 2.8%; P = 0.090). The 30-day readmission rate was comparable (CS: 12.9% vs. PS: 11.9%; P = 0.400), but PS patients were more likely to be readmitted for respiratory complications, while CS patients were readmitted primarily for heart failure.</p><p><strong>Conclusions: </strong>This study underscores the distinct clinical profiles of PS and CS. Although CS is less prevalent, it is associated with a higher cardiovascular burden and healthcare costs. Both groups exhibited similar mortality and readmission rates, though their readmission causes differed. These findings highlight the need for targeted management strategies for PS and CS to optimize patient outcomes and resource utilization.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"15 2","pages":"149-155"},"PeriodicalIF":1.3000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089025/pdf/","citationCount":"0","resultStr":"{\"title\":\"Understanding the prevalence, in-hospital mortality and readmission rates amongst pulmonary vs cardiac sarcoidosis patients: insights from a nationwide registry.\",\"authors\":\"Shivang Chaudhary, Kaushik Gokul, Simran Bhimani, Anand Maligireddy, Nirav Arora, Lolita Golemi, Adam Kilian, Ravi Nayak, Deana Mikhalkova, Chaitanya Rojulpote, Chien-Jung Lin\",\"doi\":\"10.62347/WJWP6904\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Sarcoidosis is a multisystem granulomatous disorder, with pulmonary sarcoidosis (PS) affecting approximately 90% of patients and cardiac sarcoidosis (CS) being less common but associated with severe clinical implications. While PS is primarily characterized by respiratory symptoms, CS can lead to serious complications like heart failure and arrhythmias, contributing to sarcoidosis-related mortality. This study aims to compare the prevalence, in-hospital mortality, 30-day readmission rates, and healthcare costs between PS and CS patients using data from the Nationwide Readmissions Database (NRD).</p><p><strong>Methods: </strong>Data were extracted from the NRD for adult patients diagnosed with PS or CS from January 2016 to December 2020. Baseline demographics, comorbidities, in-hospital outcomes, and 30-day readmission rates were analyzed. Statistical comparisons were made using appropriate tests for categorical and continuous variables.</p><p><strong>Results: </strong>Among 101,365 patients, 96,905 had PS and 4,460 had CS. CS patients experienced significantly higher rates of cardiovascular complications, such as heart failure (77.1% vs. 31.1%) and arrhythmias (75.8% vs. 27.7%), and incurred higher hospital charges ($59,520 vs. $40,249; P < 0.001). In-hospital mortality was similar between groups (CS: 2.4% vs. PS: 2.8%; P = 0.090). The 30-day readmission rate was comparable (CS: 12.9% vs. PS: 11.9%; P = 0.400), but PS patients were more likely to be readmitted for respiratory complications, while CS patients were readmitted primarily for heart failure.</p><p><strong>Conclusions: </strong>This study underscores the distinct clinical profiles of PS and CS. Although CS is less prevalent, it is associated with a higher cardiovascular burden and healthcare costs. Both groups exhibited similar mortality and readmission rates, though their readmission causes differed. These findings highlight the need for targeted management strategies for PS and CS to optimize patient outcomes and resource utilization.</p>\",\"PeriodicalId\":7427,\"journal\":{\"name\":\"American journal of cardiovascular disease\",\"volume\":\"15 2\",\"pages\":\"149-155\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089025/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of cardiovascular disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62347/WJWP6904\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cardiovascular disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/WJWP6904","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:结节病是一种多系统肉芽肿性疾病,肺结节病(PS)影响约90%的患者,心脏结节病(CS)不太常见,但具有严重的临床意义。虽然PS主要以呼吸系统症状为特征,但CS可导致严重的并发症,如心力衰竭和心律失常,导致结节病相关死亡。本研究旨在利用全国再入院数据库(NRD)的数据,比较PS和CS患者的患病率、住院死亡率、30天再入院率和医疗费用。方法:从2016年1月至2020年12月诊断为PS或CS的成人患者的NRD中提取数据。分析基线人口统计学、合并症、住院结果和30天再入院率。采用适当的分类变量和连续变量检验进行统计比较。结果:101365例患者中,96905例PS, 4460例CS。CS患者的心血管并发症发生率明显更高,如心力衰竭(77.1% vs. 31.1%)和心律失常(75.8% vs. 27.7%),住院费用也更高(59,520美元vs. 40,249美元;P < 0.001)。两组间住院死亡率相似(CS: 2.4% vs. PS: 2.8%;P = 0.090)。30天再入院率相当(CS: 12.9% vs PS: 11.9%;P = 0.400),但PS患者更容易因呼吸系统并发症再次入院,而CS患者主要因心力衰竭再次入院。结论:本研究强调了PS和CS的不同临床特征。虽然CS不太普遍,但它与较高的心血管负担和医疗费用相关。两组的死亡率和再入院率相似,但再入院原因不同。这些发现强调需要针对PS和CS制定有针对性的管理策略,以优化患者预后和资源利用。
Understanding the prevalence, in-hospital mortality and readmission rates amongst pulmonary vs cardiac sarcoidosis patients: insights from a nationwide registry.
Objectives: Sarcoidosis is a multisystem granulomatous disorder, with pulmonary sarcoidosis (PS) affecting approximately 90% of patients and cardiac sarcoidosis (CS) being less common but associated with severe clinical implications. While PS is primarily characterized by respiratory symptoms, CS can lead to serious complications like heart failure and arrhythmias, contributing to sarcoidosis-related mortality. This study aims to compare the prevalence, in-hospital mortality, 30-day readmission rates, and healthcare costs between PS and CS patients using data from the Nationwide Readmissions Database (NRD).
Methods: Data were extracted from the NRD for adult patients diagnosed with PS or CS from January 2016 to December 2020. Baseline demographics, comorbidities, in-hospital outcomes, and 30-day readmission rates were analyzed. Statistical comparisons were made using appropriate tests for categorical and continuous variables.
Results: Among 101,365 patients, 96,905 had PS and 4,460 had CS. CS patients experienced significantly higher rates of cardiovascular complications, such as heart failure (77.1% vs. 31.1%) and arrhythmias (75.8% vs. 27.7%), and incurred higher hospital charges ($59,520 vs. $40,249; P < 0.001). In-hospital mortality was similar between groups (CS: 2.4% vs. PS: 2.8%; P = 0.090). The 30-day readmission rate was comparable (CS: 12.9% vs. PS: 11.9%; P = 0.400), but PS patients were more likely to be readmitted for respiratory complications, while CS patients were readmitted primarily for heart failure.
Conclusions: This study underscores the distinct clinical profiles of PS and CS. Although CS is less prevalent, it is associated with a higher cardiovascular burden and healthcare costs. Both groups exhibited similar mortality and readmission rates, though their readmission causes differed. These findings highlight the need for targeted management strategies for PS and CS to optimize patient outcomes and resource utilization.